US › Healthcare

Pyxis Oncology Inc (PYXS)

US · Healthcare · Biotechnology

$1.66+3.11%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

Revenue YoY

-100.0%

Net profit

$-25.3M

EPS

$-0.40

EPS estimate

$-0.34

EPS came in at -0.40 against a street estimate of -0.34 — a miss of 17.6%.

Key statistics

Market cap

$198.3M

Forward P/E

0.0

P/B

11.92

Book value

$0.18

EPS (TTM)

$-1.40

52-week high

$5.55

52-week low

$1.03

50-day MA

$2.60

200-day MA

$2.16

Beta

1.41

Analyst view

Analysts rate Pyxis Oncology Inc a strong buy (8 buy, 1 hold, 0 sell out of 9) with an average price target of $8.56.

Shareholding

Insiders

10.08%

Institutions

55.37%

Largest institutional holders

Fund	Stake
GordonMD Global Investments LP	8.39%
Pfizer Inc	5.89%
LAURION CAPITAL MANAGEMENT LP	4.10%
Vanguard Capital Management, LLC	1.74%
Atle Fund Management AB	0.81%
BlackRock Inc	0.73%
Palo Alto Investors, LLC	0.72%
Marshall Wace Asset Management Ltd	0.70%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Pyxis Oncology Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.